Anti-Tregs Immune-modulating Anti-cancer Technology

Creative Biolabs has extensive experience in the field of cancer vaccines and now provides anti-Tregs immune-modulating based anti-cancer technology for the treatment of cancer. The technology is an innovative investigational approach designed to activate the body's endogenous anti-regulatory T cells (anti-Tregs) to target regulatory as well as malignant cells. Because the technology is based on the immune-modulatory function of the vaccines, the vaccines activate both CD4 and CD8 anti-Tregs.

The immune system consists of many types of regulatory cells [e.g., regulatory T cells (Tregs), M2 macrophages, myeloid-derived suppressor cells (MDSCs), and different dendritic cell subtypes], which control the strength of the immune response. These regulatory immune cells suppress and terminate immune reactions to maintain the immune balance. Counterregulatory responses are essential for the immune system because they limit the intensity and extent of immune responses that might otherwise damage the host. Numerous cancer cell types have adapted the phenotype of regulatory immune cells and display elevated expression of immunoregulatory proteins. Therefore, cancer cells themselves can also be directly targeted by anti-Tregs.

Creative Biolabs' anti-Tregs immune-modulating anti-cancer technology is based on targeting and activating anti-Tregs that can specifically remove unwanted cells in the tumor microenvironment by long peptide vaccination. Natural immunity against anti-Treg antigens allows for robust anti-Treg responses using a simple vaccination method. In addition, since anti-Tregs are naturally present in vivo, there must be a mechanism to ensure the immune homeostasis in check, thus the risk of causing autoimmune-related adverse events is considered minimal.

Vaccines Targeting IDO

Indoleamine 2,3-dioxygenase (IDO) is a very attractive target in the design of new anti-cancer drugs. It is a natural immunoregulatory mechanism that contributes to immune suppression and tolerance in a variety of settings. It directly inhibits the proliferation and differentiation of effector T cells and significantly enhances the inhibitory activity of regulatory T cells. Creative Biolabs provides IDO vaccine development for cancer therapy by helping the immune system to respond effectively to tumor antigens.

Vaccines Targeting TDO

Tryptophan 2,6-dioxygenase (TDO) might be another interesting target for therapeutic vaccinations against both cancer cells and local immune paralysis in the tumor microenvironment. Similar to IDO, TDO mRNA expression was also found in human tumors. It is possible to restore Th1 response towards TD1 in cancer patients in the setting of a TDO-based therapeutic vaccine in which T cells are reactivated outside the tumor site.

Vaccines Targeting Arginase

Activation of arginase-specific T cells by therapeutic arginase vaccines is attractive because arginase-expressing myeloid cells are major players involved in the immunosuppressive microenvironment found in many tumors. Arginase vaccination could induce Th1 inflammation at tumor sites where regulatory myeloid cells otherwise prevent lymphocyte infiltration. Creative Biolabs has extensive experience in the field of cancer vaccines and can provide arginase vaccine development for cancer therapy.

Vaccines Targeting PD-1/PD-L1

Activation of PD-1/PD-L1 signaling could serve as a mechanism for tumors to evade an antigen-specific T-cell immunologic response. Therefore, the hypothesis was developed that PD-1/PD-L1 blockade may be effective cancer immunotherapy. Early preclinical evidence provided the rationale for PD-1 and PD-L1 blockade as a potential form of cancer immunotherapy given that activation of the PD-1/PD-L1 axis putatively served as a mechanism for tumor evasion of host tumor antigen-specific T-cell immunity. Creative Biolabs has extensive experience in the field of cancer vaccines and can provide PD-1/PD-L1 blockade development services for the treatment of cancer with durable responses and extended overall survival.

Vaccines Targeting CTLA-4

Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) plays an important role in restraining the adaptive immune response of T-cells towards a variety of antigens. It has demonstrated promise in a variety of malignancies. To improve on the number of patients who benefit from immune checkpoint blockade, CTLA-4, and PD-1/PD-L1 antibodies are combined and with other anticancer agents, such as targeted therapy, chemotherapy, radiation therapy, and other immunotherapies.

Vaccines Targeting CCL22

C-C motif chemokine 22 (CCL22) plays a key role in a variety of diseases, including atopic dermatitis, allergic rhinitis, and lymphoma. Tumor cells and tumor-associated macrophages secrete the chemokine CCL22, which attracts and recruits Tregs to the microenvironment. The production of CCL22 correlates with the accumulation of Tregs in many solid cancers. Therapeutic vaccination against CCL22 is another way to target cells in the tumor microenvironment and modulating the immunosuppressive environment. This approach should be an attractive method to improve anti-cancer immunity in cancers that produce CCL22.

Creative Biolabs is a leader in the field of vaccine development and has focused on cancer vaccines for years. We have experienced experts and advanced platforms that are able to provide excellent services. If you are interested in our services, please contact us for more details.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.